Shots:

• Sanofi has signed an exclusive worldwide licensing agreement with C4XD worth up to $492.94M million- for C4XD’s oral pre-clinical IL-17A inhibitor program
• C4XD to receive $8.33M up front and is eligible to receive up to $484.60M as development- regulatory and commercial milestones including $13.09M as pre-clinical milestones along with royalties
• Sanofi will develop and commercialize an oral therapy for inflammatory diseases and will continue to work with the C4XD team to access its 4D Conformetrix technology- following the advancement of the program towards clinical studies

  Ref: GlobeNewswire | Image: Sanofi